Phase 3 RCT in 194 adults with insomnia disorder in China: after 1 month, lemborexant 10 mg shortened latency to persistent sleep more than placebo (mean −39.5 vs −21.7 min; post hoc transformation p=0.0096) and improved sleep efficiency and WASO.
Secondary analysisn = 194
Mi et al. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder